澳门六合彩开奖记录

Phishing warning 01-May-2024
We are aware of phishing emails targeting speakers of events whose names appear on our events pages. If you are unsure if an email regarding event registration or accommodation has come from us please contact us and do not provide any credit card details or personal information.

澳门六合彩开奖记录 Desktop Seminar Series with 澳门六合彩开奖记录 Medicinal Chemistry & 澳门六合彩开奖记录-BMCS

9 December 2021 14:00-15:20, Online, United Kingdom


Introduction
Welcome to the latest 澳门六合彩开奖记录 Desktop Seminars hosted by 澳门六合彩开奖记录 Medicinal Chemistry and the 澳门六合彩开奖记录-BMCS (Biological & Medicinal Chemistry Sector). Each 80-minute seminar in this free series will feature talks from an 澳门六合彩开奖记录 Medicinal Chemistry Editorial Board member and a BMCS prize winner/澳门六合彩开奖记录 Medicinal Chemistry author.

Join 澳门六合彩开奖记录 Medicinal Chemistry Editorial Board Member Dr Paola Castaldi (LifeMine Therapeutics, USA) and Professor Matthias Wymann (University of Basel, Switzerland) in our second session as part of the Desktop Seminar Series with 澳门六合彩开奖记录 Medicinal Chemistry and the BMCS. Introductions will be given by 澳门六合彩开奖记录 Medicinal Chemistry Executive Editor, Dr. Katie Lim, and Chairman of the 澳门六合彩开奖记录-BMCS, Dr Andrew Williams.

This 80-minute seminar will allow researchers of all professional levels to connect, share ideas, and ask questions. Be sure to register for the free seminar series today!

Speakers

Professor Matthias Wymann
鈥淭argeting PI3K and mTOR - therapeutic gain by specificity?鈥

Dr Paola Castaldi
鈥淢echanistic insights of a CDK9 inhibitor via orthogonal proteomics methods鈥

Programme

2:00 PM GMT (3:00 PM CET / 9:00 AM EST) 鈥 Welcome & introduction

2:05 PM GMT (3:05 PM CET / 9:05 AM EST) 鈥 鈥淭argeting PI3K and mTOR - therapeutic gain by specificity?鈥, Matthias Wymann (University of Basel)"

2:30 PM GMT (3:30 PM CET / 9:30 AM EST) 鈥 Q&A with Professor Matthias Wymann 

2:40 PM GMT (3:40 PM CET / 9:40 AM EST) 鈥 鈥淢echanistic insights of a CDK9 inhibitor via orthogonal proteomics methods," Paola Castaldi (LifeMine Therapeutics)

3:05 PM GMT (4:05 PM CET / 10:05 AM EST) 鈥 Q&A with Dr Paola Castaldi

3:15 PM GMT (4:15 PM CET / 10:15 AM EST) 鈥 Closing remarks
 
Speakers
Professor Matthias Wymann, University of Basel, Switzerland

Matthias Wymann leads the “Cancer & Immunobiology” group at the Department of Biomedicine, University of Basel.
 
Wymann has introduced the first phosphoinositide 3-kinase (PI3K) inhibitor, wortmannin, and elucidated inhibitor PI3K-interactions. Recent research focused on the molecular function and physiologic importance of PI3Ks, in particular PI3Kg in chronic inflammation and allergy. PI3Kg was shown to relay signals emerging from G protein-coupled receptors (GPCRs) to leukocyte migration and mast cell degranulation. PI3Kg knock-in strategies illustrated lately, that the PI3Kg protein, but not lipid kinase activity is required for the down-regulation of cardiac cAMP, and PI3Kg thus affects heart contractile responses. Wymann has also promoted efforts to develop PI3Kg–specific, bioavailable inhibitors, which demonstrated the feasibility to target PI3Kg in chronic inflammation and allergy, e.g. rheumatoid arthritis and atherosclerosis (EU FP5 ACID and FP6 MAIN projects). Current research concentrates on the role of PI3K and PI3K-related kinases in cancer and inflammation, as well as the development of chemical biological tools to improve spacial and temporal resolution in phosphoinositide signalling, and translational development of PI3K and mTOR kinase inhibitors.


Dr Paola Castaldi, LifeMine Therapeutics, United States

Paola Castaldi is an experienced and passionate chemical biologist with experience in leading multidisciplinary teams supporting programs across several therapeutic areas and stages.  Her drive towards embedding state-of-the-art technologies to drug discovery and development, resulted in several contributions to target identification, mechanism of action and safety deconvolution of therapeutics.
Before joining LifeMine Therapeutics, Paola headed the Chemical Biology & Proteomics department at AstraZeneca. Over the years Paola was responsible for the build of a state-of-the-art chemical biology and mass spectrometry hub with global impact across all therapeutic areas and platforms. Notably she played a critical role to the establishment of the protein degradation and the multi-omics initiatives.
Before AstraZeneca, Paola was a key contributor of the Chemical Genetics group at Sanofi Oncology, Cambridge, MA with a focus on phenotypic drug discovery projects for the Wnt and KRAS oncogenic pathways.
Between other responsibilities, Paola is part of the SAB for the Chemical Biology Doctorate Program at Imperial College London and has authored more than 25 peer-reviewed articles.
Paola completed her undergraduate studies in pharmaceutical chemistry and received her Laurea (MSc) at University of Padova, Italy. She then went on to conduct graduate research studies at Imperial College London, UK and postdoctoral studies at UCSD and Boston University.



Venue
GoToWebinar

GoToWebinar, Online, United Kingdom

Organised by
Contact information
Search
 
 
Showing all upcoming events
Start Date
End Date
Location
Subject area
Event type

Advertisement
Spotlight


E-mail Enquiry
*
*
*
*